GLOBAL OPHTHALMIC DRUGS & DEVICES MARKET FORECAST 2017-2025
KEY FINDINGS
The global ophthalmic drugs market is estimated to grow at an approximate CAGR of 7.86% during the period of 2017 and 2024. An existing predominance and increase in the number of eye disorders with growing geriatric population all over the world are the primary drivers responsible for the market growth. With increasing awareness of ophthalmic drugs among the consumers and patients is anticipated to proliferate the market growth.
MARKET INSIGHTS
The ophthalmic drugs market is segmented on the basis of End-user, Prescription type, and Geography. The Prescription type ophthalmic drugs market is segregated into Prescription Market for Ophthalmic Drugs and OTC (Over the Counter Drugs) Market for Ophthalmic Drugs. The End-user ophthalmic drugs market is segregated into Hospitals, Eye Clinics, Diagnostic Centers, and Patients. The ophthalmic drugs market on the basis of Geography is segregated into Asia-Pacific, Europe, North America, Middle East & Africa and Central & South America.
The technological advancements, rise in eye disorders, growth in geriatric population, cataract surgeries and upsurge in healthcare expenditure are dominant drivers for the growth of ophthalmic drugs market. A vast scope for ophthalmic drugs market is created with the predominance of eye-related disorders and ailments. One major cause for half-blindness and decreased vision is Cataract with the highest percentage accountable of worldwide visual impairment. Cataract surgery is risk-free and secure kind of surgery; the safety has led to an increase in the cataract surgeries. The boost in Health expenditure has boosted the consumer spending indirectly driving the ophthalmic drugs market.
REGIONAL INSIGHTS
North America accounts for the largest market share in the global ophthalmic drugs market. Europe accounts for a second largest market share in the global ophthalmic drugs market. Asia-Pacific is estimated to expand at the highest CAGR during the forecast period. Asia-Pacific is also anticipated to emerge as a leading destination for drug development during the forecast years. The rise in aged population and existence of dominant market players in the regions are driving the regional markets. The Middle East & Africa and Central & South America ophthalmic drugs market are projected to expand during the forecast years with the rise in aged population and predominance of eye ailments amongst the population.
COMPETITIVE INSIGHTS
The predominant ophthalmic drugs companies in the global market are Bayer, Akorn, Johnson and Johnson, Abbott Laboratories, Valeant, Allergan Inc., Regeneron, Merck & Co., Pfizer Inc., Lpath Incorporated, Novartis Ag, Roche Holding Ag, Eyegate Pharmaceuticals, GlaxoSmithKline, Santen Pharmaceutical Co. Ltd, Sun Pharmaceuticals Industries, Ltd., Senju Pharmaceutical Co., Ltd, Cipla Pharmaceuticals and EyeMed.
The global ophthalmic drugs market is estimated to grow at an approximate CAGR of 7.86% during the period of 2017 and 2024. An existing predominance and increase in the number of eye disorders with growing geriatric population all over the world are the primary drivers responsible for the market growth. With increasing awareness of ophthalmic drugs among the consumers and patients is anticipated to proliferate the market growth.
MARKET INSIGHTS
The ophthalmic drugs market is segmented on the basis of End-user, Prescription type, and Geography. The Prescription type ophthalmic drugs market is segregated into Prescription Market for Ophthalmic Drugs and OTC (Over the Counter Drugs) Market for Ophthalmic Drugs. The End-user ophthalmic drugs market is segregated into Hospitals, Eye Clinics, Diagnostic Centers, and Patients. The ophthalmic drugs market on the basis of Geography is segregated into Asia-Pacific, Europe, North America, Middle East & Africa and Central & South America.
The technological advancements, rise in eye disorders, growth in geriatric population, cataract surgeries and upsurge in healthcare expenditure are dominant drivers for the growth of ophthalmic drugs market. A vast scope for ophthalmic drugs market is created with the predominance of eye-related disorders and ailments. One major cause for half-blindness and decreased vision is Cataract with the highest percentage accountable of worldwide visual impairment. Cataract surgery is risk-free and secure kind of surgery; the safety has led to an increase in the cataract surgeries. The boost in Health expenditure has boosted the consumer spending indirectly driving the ophthalmic drugs market.
REGIONAL INSIGHTS
North America accounts for the largest market share in the global ophthalmic drugs market. Europe accounts for a second largest market share in the global ophthalmic drugs market. Asia-Pacific is estimated to expand at the highest CAGR during the forecast period. Asia-Pacific is also anticipated to emerge as a leading destination for drug development during the forecast years. The rise in aged population and existence of dominant market players in the regions are driving the regional markets. The Middle East & Africa and Central & South America ophthalmic drugs market are projected to expand during the forecast years with the rise in aged population and predominance of eye ailments amongst the population.
COMPETITIVE INSIGHTS
The predominant ophthalmic drugs companies in the global market are Bayer, Akorn, Johnson and Johnson, Abbott Laboratories, Valeant, Allergan Inc., Regeneron, Merck & Co., Pfizer Inc., Lpath Incorporated, Novartis Ag, Roche Holding Ag, Eyegate Pharmaceuticals, GlaxoSmithKline, Santen Pharmaceutical Co. Ltd, Sun Pharmaceuticals Industries, Ltd., Senju Pharmaceutical Co., Ltd, Cipla Pharmaceuticals and EyeMed.
1. RESEARCH SCOPE
1.1. STUDY GOALS
1.2. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET OVERVIEW
4. MARKET DETERMINANTS
4.1. MARKET DRIVERS
4.1.1. INCREASING GERIATRIC POPULATION GLOBALLY
4.1.2. TECHNOLOGICAL ADVANCEMENT
4.1.3. RISING PREVALENCE OF EYE DISORDERS
4.1.4. INCREASED HEALTHCARE EXPENDITURE
4.1.5. CATARACT SURGERIES ON RISE
4.2. MARKET RESTRAINTS
4.2.1. RENOWNED DRUGS GOING OFF-PATENT
4.2.2. DELAY IN DRUGS APPROVALS
4.3. MARKET OPPORTUNITIES
4.3.1. INCREASE IN DISORDER SYMPTOM AWARENESS LEADING TO HIGHER TREATMENT RATES
4.3.2. GROWING OPPORTUNITIES IN DEVELOPING ECONOMIES
5. GLOBAL OPHTHALMIC DRUGS MARKET BY PRESCRIPTION TYPE
5.1. GLOBAL PRESCRIPTION MARKET FOR OPHTHALMIC DRUGS
5.2. GLOBAL OTC (OVER THE COUNTER DRUGS) MARKET FOR OPHTHALMIC DRUGS
6. GLOBAL OPHTHALMIC DRUGS MARKET BY END USER
6.1. GLOBAL HOSPITALS OPHTHALMIC DRUGS MARKET
6.2. GLOBAL EYE CLINICS OPHTHALMIC DRUGS MARKET
6.3. GLOBAL DIAGNOSTIC CENTERS OPHTHALMIC DRUGS MARKET
6.4. GLOBAL PATIENTS OPHTHALMIC DRUGS MARKET
7. KEY ANALYTICS
7.1. VALUE CHAIN ANALYSIS
7.1.1. RESEARCH AND DEVELOPMENT
7.1.2. MANUFACTURING
7.1.3. MARKETING AND DISTRIBUTION
7.2. PORTER’S FIVE FORCES ANALYSIS
7.2.1. BARGAINING POWER BUYERS
7.2.2. BARGAINING POWER OF SUPPLIER
7.2.3. THREATS OF NEW ENTRANTS
7.2.4. THREATS OF SUBSTITUTES
7.2.5. COMPETITIVE RIVALRY
7.3. SEE-SAW ANALYSIS
8. REGIONAL ANALYSIS
8.1. NORTH AMERICA
8.1.1. UNITED STATES (U.S.)
8.1.2. CANADA
8.1.3. MEXICO
8.2. EUROPE
8.2.1. GERMANY
8.2.2. UNITED KINGDOM (UK)
8.2.3. RUSSIA
8.2.4. FRANCE
8.2.5. ITALY
8.2.6. SPAIN
8.3. ASIA PACIFIC
8.3.1. CHINA
8.3.2. INDIA
8.3.3. SOUTH KOREA
8.3.4. JAPAN
8.3.5. AUSTRALIA
8.4. MIDDLE EAST & AFRICA
8.5. CENTRAL &SOUTH AMERICA
9. COMPETITIVE LANDSCAPE
9.1. ABBOTT LABORATORIES
9.2. ALLERGAN INC.
9.3. JOHNSON AND JOHNSON
9.4. BAYER
9.5. VALEANT
9.6. REGENERON
9.7. AKORN
9.8. EYEMED
9.9. SENJU PHARMACEUTICAL CO., LTD
9.10. PFIZER INC.
9.11. MERCK & CO.
9.12. NOVARTIS AG
9.13. GLAXOSMITHKLINE
9.14. EYEGATE PHARMACEUTICALS
9.15. LPATH INCORPORATED
9.16. ROCHE HOLDING AG
9.17. SANTEN PHARMACEUTICAL CO. LTD
9.18. CIPLA PHARMACEUTICALS
9.19. SUN PHARMACEUTICALS INDUSTRIES, LTD.
1.1. STUDY GOALS
1.2. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET OVERVIEW
4. MARKET DETERMINANTS
4.1. MARKET DRIVERS
4.1.1. INCREASING GERIATRIC POPULATION GLOBALLY
4.1.2. TECHNOLOGICAL ADVANCEMENT
4.1.3. RISING PREVALENCE OF EYE DISORDERS
4.1.4. INCREASED HEALTHCARE EXPENDITURE
4.1.5. CATARACT SURGERIES ON RISE
4.2. MARKET RESTRAINTS
4.2.1. RENOWNED DRUGS GOING OFF-PATENT
4.2.2. DELAY IN DRUGS APPROVALS
4.3. MARKET OPPORTUNITIES
4.3.1. INCREASE IN DISORDER SYMPTOM AWARENESS LEADING TO HIGHER TREATMENT RATES
4.3.2. GROWING OPPORTUNITIES IN DEVELOPING ECONOMIES
5. GLOBAL OPHTHALMIC DRUGS MARKET BY PRESCRIPTION TYPE
5.1. GLOBAL PRESCRIPTION MARKET FOR OPHTHALMIC DRUGS
5.2. GLOBAL OTC (OVER THE COUNTER DRUGS) MARKET FOR OPHTHALMIC DRUGS
6. GLOBAL OPHTHALMIC DRUGS MARKET BY END USER
6.1. GLOBAL HOSPITALS OPHTHALMIC DRUGS MARKET
6.2. GLOBAL EYE CLINICS OPHTHALMIC DRUGS MARKET
6.3. GLOBAL DIAGNOSTIC CENTERS OPHTHALMIC DRUGS MARKET
6.4. GLOBAL PATIENTS OPHTHALMIC DRUGS MARKET
7. KEY ANALYTICS
7.1. VALUE CHAIN ANALYSIS
7.1.1. RESEARCH AND DEVELOPMENT
7.1.2. MANUFACTURING
7.1.3. MARKETING AND DISTRIBUTION
7.2. PORTER’S FIVE FORCES ANALYSIS
7.2.1. BARGAINING POWER BUYERS
7.2.2. BARGAINING POWER OF SUPPLIER
7.2.3. THREATS OF NEW ENTRANTS
7.2.4. THREATS OF SUBSTITUTES
7.2.5. COMPETITIVE RIVALRY
7.3. SEE-SAW ANALYSIS
8. REGIONAL ANALYSIS
8.1. NORTH AMERICA
8.1.1. UNITED STATES (U.S.)
8.1.2. CANADA
8.1.3. MEXICO
8.2. EUROPE
8.2.1. GERMANY
8.2.2. UNITED KINGDOM (UK)
8.2.3. RUSSIA
8.2.4. FRANCE
8.2.5. ITALY
8.2.6. SPAIN
8.3. ASIA PACIFIC
8.3.1. CHINA
8.3.2. INDIA
8.3.3. SOUTH KOREA
8.3.4. JAPAN
8.3.5. AUSTRALIA
8.4. MIDDLE EAST & AFRICA
8.5. CENTRAL &SOUTH AMERICA
9. COMPETITIVE LANDSCAPE
9.1. ABBOTT LABORATORIES
9.2. ALLERGAN INC.
9.3. JOHNSON AND JOHNSON
9.4. BAYER
9.5. VALEANT
9.6. REGENERON
9.7. AKORN
9.8. EYEMED
9.9. SENJU PHARMACEUTICAL CO., LTD
9.10. PFIZER INC.
9.11. MERCK & CO.
9.12. NOVARTIS AG
9.13. GLAXOSMITHKLINE
9.14. EYEGATE PHARMACEUTICALS
9.15. LPATH INCORPORATED
9.16. ROCHE HOLDING AG
9.17. SANTEN PHARMACEUTICAL CO. LTD
9.18. CIPLA PHARMACEUTICALS
9.19. SUN PHARMACEUTICALS INDUSTRIES, LTD.
LIST OF TABLES
TABLE 1 GLOBAL OPHTHALMIC DRUGS MARKET REVENUE BY GEOGRAPHY 2017-2024($ MILLION)
TABLE 2 COMMON CAUSES OF LOSS OF VISION IN THE ELDERLY
TABLE 3 EYE DRUGS GONE OFF-PATENT OFF
TABLE 4 GLOBAL OPHTHALMIC DRUGS MARKET BY PRESCRIPTION TYPE 2017 - 2024 ($ MILLION)
TABLE 5 RECENT FDA APPROVED DRUGS FOR OPHTHALMOLOGY
TABLE 6 DETAILS OF SOME KEY PRESCRIPTION DRUGS
TABLE 7 OPHTHALMIC DRUGS PRODUCTS FOR OVER-THE-COUNTER HUMAN USE
TABLE 8 GLOBAL OPHTHALMIC DRUGS MARKET BY END USER 2017 - 2024 ($ MILLION)
TABLE 9 NORTH AMERICA MARKET ESTIMATES AND FORECAST BY END-USER 2017-2024 ($ MILLION)
TABLE 10 NORTH AMERICA MARKET ESTIMATES AND FORECAST BY REGION 2017-2024 ($ MILLION)
TABLE 11 U.S. MARKET ESTIMATES AND FORECAST BY END-USER 2017-2024 ($ MILLION)
TABLE 12 U.S. HOSPITAL FACT SHEET, 2016
TABLE 13 CANADA MARKET ESTIMATES AND FORECAST BY END-USER 2017-2024 ($ MILLION)
TABLE 14 MEXICO MARKET ESTIMATES AND FORECAST BY END-USER 2017-2024 ($ MILLION)
TABLE 15 EUROPE MARKET ESTIMATES AND FORECAST BY END-USER 2017-2024 ($ MILLION)
TABLE 16 EXTRAPOLATION OF PREVALENCE RATE OF GLAUCOMA BY COUNTRIES
TABLE 17 EUROPE MARKET ESTIMATES AND FORECAST BY REGION 2017–2024 ($ MILLION)
TABLE 18 GERMANY MARKET ESTIMATES AND FORECAST BY END-USER 2017-2024($ MILLION)
TABLE 19 UK MARKET ESTIMATES AND FORECAST BY END-USER 2017-2024 ($ MILLION)
TABLE 20 RUSSIA MARKET ESTIMATES AND FORECAST BY END-USER 2017-2024 ($ MILLION)
TABLE 21 NUMBER OF HOSPITALS IN RUSSIAN COUNTRIES, 2015
TABLE 22 FRANCE MARKET ESTIMATES AND FORECAST BY END-USER 2017-2024 ($ MILLION)
TABLE 23 FRANCE MARKET ESTIMATES AND FORECAST 2017-2024 ($ MILLION)
TABLE 24 ITALY MARKET ESTIMATES AND FORECAST BY END-USER 2017-2024 ($ MILLION)
TABLE 25 SPAIN MARKET ESTIMATES AND FORECAST BY END-USER 2017-2024 ($ MILLION)
TABLE 26 ASIA-PACIFIC MARKET ESTIMATES AND FORECAST BY END-USER 2017-2024 ($ MILLION)
TABLE 27 ASIA-PACIFIC MARKET ESTIMATES AND FORECAST BY REGION 2017-2024 ($ MILLION)
TABLE 28 PREVALENCE RATE OF EYE RELATED DISEASES IN CHINA, 2014
TABLE 29 CHINA MARKET ESTIMATES AND FORECAST BY END-USER 2017-2024 ($ MILLION)
TABLE 30 INDIA MARKET ESTIMATES AND FORECAST BY END-USER 2017-2024 ($ MILLION)
TABLE 31 HUMAN RESOURCE NEEDS FOR EYE CARE IN INDIA
TABLE 32 SOUTH KOREA MARKET ESTIMATES AND FORECAST BY END-USER 2017-2024 ($ MILLION)
TABLE 33 JAPAN MARKET ESTIMATES AND FORECAST BY END-USER 2017-2024 ($ MILLION)
TABLE 34 AUSTRALIA MARKET ESTIMATES AND FORECAST BY END-USER 2017-2024 ($ MILLION)
TABLE 35 MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2017-2024 ($ MILLION)
TABLE 36 CENTRAL & SOUTH AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2017-2024 ($ MILLION)
TABLE 1 GLOBAL OPHTHALMIC DRUGS MARKET REVENUE BY GEOGRAPHY 2017-2024($ MILLION)
TABLE 2 COMMON CAUSES OF LOSS OF VISION IN THE ELDERLY
TABLE 3 EYE DRUGS GONE OFF-PATENT OFF
TABLE 4 GLOBAL OPHTHALMIC DRUGS MARKET BY PRESCRIPTION TYPE 2017 - 2024 ($ MILLION)
TABLE 5 RECENT FDA APPROVED DRUGS FOR OPHTHALMOLOGY
TABLE 6 DETAILS OF SOME KEY PRESCRIPTION DRUGS
TABLE 7 OPHTHALMIC DRUGS PRODUCTS FOR OVER-THE-COUNTER HUMAN USE
TABLE 8 GLOBAL OPHTHALMIC DRUGS MARKET BY END USER 2017 - 2024 ($ MILLION)
TABLE 9 NORTH AMERICA MARKET ESTIMATES AND FORECAST BY END-USER 2017-2024 ($ MILLION)
TABLE 10 NORTH AMERICA MARKET ESTIMATES AND FORECAST BY REGION 2017-2024 ($ MILLION)
TABLE 11 U.S. MARKET ESTIMATES AND FORECAST BY END-USER 2017-2024 ($ MILLION)
TABLE 12 U.S. HOSPITAL FACT SHEET, 2016
TABLE 13 CANADA MARKET ESTIMATES AND FORECAST BY END-USER 2017-2024 ($ MILLION)
TABLE 14 MEXICO MARKET ESTIMATES AND FORECAST BY END-USER 2017-2024 ($ MILLION)
TABLE 15 EUROPE MARKET ESTIMATES AND FORECAST BY END-USER 2017-2024 ($ MILLION)
TABLE 16 EXTRAPOLATION OF PREVALENCE RATE OF GLAUCOMA BY COUNTRIES
TABLE 17 EUROPE MARKET ESTIMATES AND FORECAST BY REGION 2017–2024 ($ MILLION)
TABLE 18 GERMANY MARKET ESTIMATES AND FORECAST BY END-USER 2017-2024($ MILLION)
TABLE 19 UK MARKET ESTIMATES AND FORECAST BY END-USER 2017-2024 ($ MILLION)
TABLE 20 RUSSIA MARKET ESTIMATES AND FORECAST BY END-USER 2017-2024 ($ MILLION)
TABLE 21 NUMBER OF HOSPITALS IN RUSSIAN COUNTRIES, 2015
TABLE 22 FRANCE MARKET ESTIMATES AND FORECAST BY END-USER 2017-2024 ($ MILLION)
TABLE 23 FRANCE MARKET ESTIMATES AND FORECAST 2017-2024 ($ MILLION)
TABLE 24 ITALY MARKET ESTIMATES AND FORECAST BY END-USER 2017-2024 ($ MILLION)
TABLE 25 SPAIN MARKET ESTIMATES AND FORECAST BY END-USER 2017-2024 ($ MILLION)
TABLE 26 ASIA-PACIFIC MARKET ESTIMATES AND FORECAST BY END-USER 2017-2024 ($ MILLION)
TABLE 27 ASIA-PACIFIC MARKET ESTIMATES AND FORECAST BY REGION 2017-2024 ($ MILLION)
TABLE 28 PREVALENCE RATE OF EYE RELATED DISEASES IN CHINA, 2014
TABLE 29 CHINA MARKET ESTIMATES AND FORECAST BY END-USER 2017-2024 ($ MILLION)
TABLE 30 INDIA MARKET ESTIMATES AND FORECAST BY END-USER 2017-2024 ($ MILLION)
TABLE 31 HUMAN RESOURCE NEEDS FOR EYE CARE IN INDIA
TABLE 32 SOUTH KOREA MARKET ESTIMATES AND FORECAST BY END-USER 2017-2024 ($ MILLION)
TABLE 33 JAPAN MARKET ESTIMATES AND FORECAST BY END-USER 2017-2024 ($ MILLION)
TABLE 34 AUSTRALIA MARKET ESTIMATES AND FORECAST BY END-USER 2017-2024 ($ MILLION)
TABLE 35 MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2017-2024 ($ MILLION)
TABLE 36 CENTRAL & SOUTH AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2017-2024 ($ MILLION)
LIST OF FIGURES
FIGURE 1 GLOBAL OPHTHALMIC DRUGS MARKET BY GEOGRAPHY 2012 AND 2022 (%)
FIGURE 2 GLOBAL OPHTHALMIC DRUGS MARKET BY PRESCRIPTION TYPE 2017-2024 ($ MILLION)
FIGURE 3 THE POPULATION OF PEOPLE AGED 65 AND OVER WILL DOUBLE IN THE NEXT 25 YEARS (IN MILLIONS)
FIGURE 4 PROJECTIONS FOR THE PROPORTION OF GERIATRIC (60+) POPULATION IN 2015, 2030 & 2050
FIGURE 5 WORLDWIDE PREVALENCE OF PRESBYOPIA 2015, 2020 & 2050 (BILLION)
FIGURE 6 PREVALENCE OF GLAUCOMA AT GLOBAL LEVEL IN 2013, 2020 & 2040 (MILLION)
FIGURE 7 GLOBAL HEALTHCARE EXPENDITURE (% OF GDP) 2012-2014
FIGURE 8 HEALTHCARE EXPENDITURE OF DEVELOPED ECONOMIES AS % OF THEIR GDP IN 2014
FIGURE 9 HEALTHCARE EXPENDITURE OF DEVELOPING ECONOMIES AS % OF THEIR GDP IN 2014
FIGURE 10 OPHTHALMIC DRUGS BY TYPE IN 2016 (%)
FIGURE 11 GLOBAL HOSPITALS OPHTHALMIC DRUGS MARKET 2017 - 2024 ($ MILLION)
FIGURE 12 TOTAL OPHTHALMIC CARE HOSPITAL IN U.S. 2014
FIGURE 13 GLOBAL EYE CLINICS OPHTHALMIC DRUGS MARKET 2017 - 2024 ($ MILLION)
FIGURE 14 EYE DISEASES CASES IN MILLION ABOVE AGE OF 40 IN AMERICA 2015
FIGURE 15 GLOBAL DIAGNOSTIC CENTERS OPHTHALMIC DRUGS MARKET 2017 - 2024 ($ MILLION)
FIGURE 16 TOTAL VISUAL IMPAIRMENT AND BLINDNESS CASES ABOVE AGE 40 IN U.S. IN 2015 (IN MILLION)
FIGURE 17 CASES ABOVE AGE 40 IN AMERICA 2014 (MILLION)
FIGURE 18 GLOBAL PATIENTS OPHTHALMIC DRUGS MARKET 2017 - 2024 ($ MILLION)
FIGURE 19 NORTH AMERICA MARKET ESTIMATES AND FORECAST 2017-2024 ($ MILLION)
FIGURE 20 U.S. POPULATION AGES 65 AND OLDER, 1960 TO 2060 (MILLION)
FIGURE 21 U.S. MARKET ESTIMATES AND FORECAST 2017-2024 ($ MILLION)
FIGURE 22 CAUSES OF VISUAL IMPAIRMENT IN U.S., 2014
FIGURE 23 CANADA MARKET ESTIMATES AND FORECAST 2017-2024 ($ MILLION)
FIGURE 24 PREVALENCE RATE OF RETINAL DISORDERS IN CANADA, 2014
FIGURE 25 FINANCIAL COST SHARE OF RETINA DISORDER TREATMENT IN CANADA
FIGURE 26 MEXICO MARKET ESTIMATES AND FORECAST 2017-2024 ($ MILLION)
FIGURE 27 PERCENTAGE OF PEOPLE AGED 65+, MEXICO (1250-2050)
FIGURE 28 PROPORTION OF DIRECT COST OF EYE DISEASE IN MEXICO, BY PAYER
FIGURE 29 EUROPE MARKET ESTIMATES AND FORECAST 2017–2024 ($ MILLION)
FIGURE 30 DEVELOPMENT OF THE EUROPEAN POPULATION AGED 65 AND OVER, 2010, 2025 & 2050 (IN MILLION)
FIGURE 31 PROPORTION OF OPTOMETRISTS AND OPTICIANS IN EUROPEAN COUNTRIES 2015
FIGURE 32 GERMANY MARKET ESTIMATES AND FORECAST 2017-2024 ($ MILLION)
FIGURE 33 POPULATION AGES 65 AND ABOVE (% OF TOTAL)
FIGURE 34 NUMBER OF LASIK SURGERIES IN GERMANY 2012-2014 (1000S)
FIGURE 35 UK MARKET ESTIMATES AND FORECAST 2017-2024 ($ MILLION)
FIGURE 36 PROJECTED NUMBER OF PEOPLE LIVING WITH SIGHT LOSS IN THE UK (IN MILLION)
FIGURE 37 RUSSIA MARKET ESTIMATES AND FORECAST 2017-2024 ($ MILLION)
FIGURE 38 POPULATION AGES 65 AND ABOVE IN FRANCE (% OF TOTAL)
FIGURE 39 POPULATION AGES 65 AND ABOVE IN ITALY (% OF TOTAL)
FIGURE 40 ITALY MARKET ESTIMATES AND FORECAST 2017-2024 ($ MILLION)
FIGURE 41 POPULATION AGES 65 AND ABOVE IN SPAIN (% OF TOTAL)
FIGURE 42 SPAIN MARKET ESTIMATES AND FORECAST 2017-2024 ($ MILLION)
FIGURE 43 ASIA-PACIFIC MARKET ESTIMATES AND FORECAST 2017-2024 ($ MILLION)
FIGURE 44 CHINA MARKET ESTIMATES AND FORECAST 2017-2024 ($ MILLION)
FIGURE 45 INDIA MARKET ESTIMATES AND FORECAST 2017-2024 ($ MILLION)
FIGURE 46 SOUTH KOREA MARKET ESTIMATES AND FORECAST 2017-2024 ($ MILLION)
FIGURE 47 NUMBER OF YEARS FOR PERCENTAGE AGED 65 AND ABOVE IN TOTAL POPULATION TO TRIPLE
FIGURE 48 POPULATION AGES 65 AND ABOVE IN JAPAN (% OF TOTAL)
FIGURE 49 JAPAN MARKET ESTIMATES AND FORECAST 2017-2024 ($ MILLION)
FIGURE 50 POPULATION AGES 65 AND ABOVE IN AUSTRALIA (% OF TOTAL)
FIGURE 51 AUSTRALIA MARKET ESTIMATES AND FORECAST 2017-2024 ($ MILLION)
FIGURE 52 MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST 2017-2024 ($ MILLION)
FIGURE 53 PATIENTS VISIT DUBAI HEALTHCARE CITY 2014-2015 (IN MILLION)
FIGURE 54 CENTRAL & SOUTH AMERICA MARKET ESTIMATES AND FORECAST 2017-2024 ($ MILLION)
FIGURE 55 AGING POPULATION GROWTH RATE, 2000-2050
FIGURE 56 AGING POPULATION IN COLOMBIA 1250-2050 (IN THOUSANDS)
FIGURE 57 GLOBAL OPHTHALMIC DRUGS MARKET SHARE 2016(%)
FIGURE 58 ABBOTT LABORATORIES REVENUE 2013-2015 ($ MILLION)
FIGURE 59 ALLERGAN INC. REVENUE 2013-2015 ($ MILLION)
FIGURE 60 JOHNSON & JOHNSON REVENUE 2013-2015 ($ MILLION)
FIGURE 61 BAYER AG REVENUE 2013-2015 ($ MILLION)
FIGURE 62 VALEANT PHARMACEUTICALS INTERNATIONAL, INC. REVENUE 2013-2015 ($ MILLION)
FIGURE 63 REGENERON PHARMACEUTICALS, INC. REVENUE 2013-2015 ($ MILLION)
FIGURE 64 EYEMED VISION CARE REVENUE 2013-2015 ($ MILLION)
FIGURE 65 PFIZER INC. REVENUE 2013-2015 ($ MILLION)
FIGURE 66 MERCK & CO., INC. REVENUE 2013-2015 ($ MILLION)
FIGURE 67 NOVARTIS AG REVENUE 2013-2015 ($ MILLION)
FIGURE 68 GLAXOSMITHKLINE REVENUE 2013-2015 ($ MILLION)
FIGURE 69 ROCHE HOLDING AG NET SALES 2013-2015 ($ MILLION)
FIGURE 70 SANTEN PHARMACEUTICAL CO. LTD NET SALES 2013-2015 ($ MILLION)
FIGURE 71 CIPLA LTD. NET SALES 2013-2015 ($ MILLION)
FIGURE 72 SUN PHARMACEUTICALS INDUSTRIES LTD. NET SALES 2013-2015 ($ MILLION)
FIGURE 1 GLOBAL OPHTHALMIC DRUGS MARKET BY GEOGRAPHY 2012 AND 2022 (%)
FIGURE 2 GLOBAL OPHTHALMIC DRUGS MARKET BY PRESCRIPTION TYPE 2017-2024 ($ MILLION)
FIGURE 3 THE POPULATION OF PEOPLE AGED 65 AND OVER WILL DOUBLE IN THE NEXT 25 YEARS (IN MILLIONS)
FIGURE 4 PROJECTIONS FOR THE PROPORTION OF GERIATRIC (60+) POPULATION IN 2015, 2030 & 2050
FIGURE 5 WORLDWIDE PREVALENCE OF PRESBYOPIA 2015, 2020 & 2050 (BILLION)
FIGURE 6 PREVALENCE OF GLAUCOMA AT GLOBAL LEVEL IN 2013, 2020 & 2040 (MILLION)
FIGURE 7 GLOBAL HEALTHCARE EXPENDITURE (% OF GDP) 2012-2014
FIGURE 8 HEALTHCARE EXPENDITURE OF DEVELOPED ECONOMIES AS % OF THEIR GDP IN 2014
FIGURE 9 HEALTHCARE EXPENDITURE OF DEVELOPING ECONOMIES AS % OF THEIR GDP IN 2014
FIGURE 10 OPHTHALMIC DRUGS BY TYPE IN 2016 (%)
FIGURE 11 GLOBAL HOSPITALS OPHTHALMIC DRUGS MARKET 2017 - 2024 ($ MILLION)
FIGURE 12 TOTAL OPHTHALMIC CARE HOSPITAL IN U.S. 2014
FIGURE 13 GLOBAL EYE CLINICS OPHTHALMIC DRUGS MARKET 2017 - 2024 ($ MILLION)
FIGURE 14 EYE DISEASES CASES IN MILLION ABOVE AGE OF 40 IN AMERICA 2015
FIGURE 15 GLOBAL DIAGNOSTIC CENTERS OPHTHALMIC DRUGS MARKET 2017 - 2024 ($ MILLION)
FIGURE 16 TOTAL VISUAL IMPAIRMENT AND BLINDNESS CASES ABOVE AGE 40 IN U.S. IN 2015 (IN MILLION)
FIGURE 17 CASES ABOVE AGE 40 IN AMERICA 2014 (MILLION)
FIGURE 18 GLOBAL PATIENTS OPHTHALMIC DRUGS MARKET 2017 - 2024 ($ MILLION)
FIGURE 19 NORTH AMERICA MARKET ESTIMATES AND FORECAST 2017-2024 ($ MILLION)
FIGURE 20 U.S. POPULATION AGES 65 AND OLDER, 1960 TO 2060 (MILLION)
FIGURE 21 U.S. MARKET ESTIMATES AND FORECAST 2017-2024 ($ MILLION)
FIGURE 22 CAUSES OF VISUAL IMPAIRMENT IN U.S., 2014
FIGURE 23 CANADA MARKET ESTIMATES AND FORECAST 2017-2024 ($ MILLION)
FIGURE 24 PREVALENCE RATE OF RETINAL DISORDERS IN CANADA, 2014
FIGURE 25 FINANCIAL COST SHARE OF RETINA DISORDER TREATMENT IN CANADA
FIGURE 26 MEXICO MARKET ESTIMATES AND FORECAST 2017-2024 ($ MILLION)
FIGURE 27 PERCENTAGE OF PEOPLE AGED 65+, MEXICO (1250-2050)
FIGURE 28 PROPORTION OF DIRECT COST OF EYE DISEASE IN MEXICO, BY PAYER
FIGURE 29 EUROPE MARKET ESTIMATES AND FORECAST 2017–2024 ($ MILLION)
FIGURE 30 DEVELOPMENT OF THE EUROPEAN POPULATION AGED 65 AND OVER, 2010, 2025 & 2050 (IN MILLION)
FIGURE 31 PROPORTION OF OPTOMETRISTS AND OPTICIANS IN EUROPEAN COUNTRIES 2015
FIGURE 32 GERMANY MARKET ESTIMATES AND FORECAST 2017-2024 ($ MILLION)
FIGURE 33 POPULATION AGES 65 AND ABOVE (% OF TOTAL)
FIGURE 34 NUMBER OF LASIK SURGERIES IN GERMANY 2012-2014 (1000S)
FIGURE 35 UK MARKET ESTIMATES AND FORECAST 2017-2024 ($ MILLION)
FIGURE 36 PROJECTED NUMBER OF PEOPLE LIVING WITH SIGHT LOSS IN THE UK (IN MILLION)
FIGURE 37 RUSSIA MARKET ESTIMATES AND FORECAST 2017-2024 ($ MILLION)
FIGURE 38 POPULATION AGES 65 AND ABOVE IN FRANCE (% OF TOTAL)
FIGURE 39 POPULATION AGES 65 AND ABOVE IN ITALY (% OF TOTAL)
FIGURE 40 ITALY MARKET ESTIMATES AND FORECAST 2017-2024 ($ MILLION)
FIGURE 41 POPULATION AGES 65 AND ABOVE IN SPAIN (% OF TOTAL)
FIGURE 42 SPAIN MARKET ESTIMATES AND FORECAST 2017-2024 ($ MILLION)
FIGURE 43 ASIA-PACIFIC MARKET ESTIMATES AND FORECAST 2017-2024 ($ MILLION)
FIGURE 44 CHINA MARKET ESTIMATES AND FORECAST 2017-2024 ($ MILLION)
FIGURE 45 INDIA MARKET ESTIMATES AND FORECAST 2017-2024 ($ MILLION)
FIGURE 46 SOUTH KOREA MARKET ESTIMATES AND FORECAST 2017-2024 ($ MILLION)
FIGURE 47 NUMBER OF YEARS FOR PERCENTAGE AGED 65 AND ABOVE IN TOTAL POPULATION TO TRIPLE
FIGURE 48 POPULATION AGES 65 AND ABOVE IN JAPAN (% OF TOTAL)
FIGURE 49 JAPAN MARKET ESTIMATES AND FORECAST 2017-2024 ($ MILLION)
FIGURE 50 POPULATION AGES 65 AND ABOVE IN AUSTRALIA (% OF TOTAL)
FIGURE 51 AUSTRALIA MARKET ESTIMATES AND FORECAST 2017-2024 ($ MILLION)
FIGURE 52 MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST 2017-2024 ($ MILLION)
FIGURE 53 PATIENTS VISIT DUBAI HEALTHCARE CITY 2014-2015 (IN MILLION)
FIGURE 54 CENTRAL & SOUTH AMERICA MARKET ESTIMATES AND FORECAST 2017-2024 ($ MILLION)
FIGURE 55 AGING POPULATION GROWTH RATE, 2000-2050
FIGURE 56 AGING POPULATION IN COLOMBIA 1250-2050 (IN THOUSANDS)
FIGURE 57 GLOBAL OPHTHALMIC DRUGS MARKET SHARE 2016(%)
FIGURE 58 ABBOTT LABORATORIES REVENUE 2013-2015 ($ MILLION)
FIGURE 59 ALLERGAN INC. REVENUE 2013-2015 ($ MILLION)
FIGURE 60 JOHNSON & JOHNSON REVENUE 2013-2015 ($ MILLION)
FIGURE 61 BAYER AG REVENUE 2013-2015 ($ MILLION)
FIGURE 62 VALEANT PHARMACEUTICALS INTERNATIONAL, INC. REVENUE 2013-2015 ($ MILLION)
FIGURE 63 REGENERON PHARMACEUTICALS, INC. REVENUE 2013-2015 ($ MILLION)
FIGURE 64 EYEMED VISION CARE REVENUE 2013-2015 ($ MILLION)
FIGURE 65 PFIZER INC. REVENUE 2013-2015 ($ MILLION)
FIGURE 66 MERCK & CO., INC. REVENUE 2013-2015 ($ MILLION)
FIGURE 67 NOVARTIS AG REVENUE 2013-2015 ($ MILLION)
FIGURE 68 GLAXOSMITHKLINE REVENUE 2013-2015 ($ MILLION)
FIGURE 69 ROCHE HOLDING AG NET SALES 2013-2015 ($ MILLION)
FIGURE 70 SANTEN PHARMACEUTICAL CO. LTD NET SALES 2013-2015 ($ MILLION)
FIGURE 71 CIPLA LTD. NET SALES 2013-2015 ($ MILLION)
FIGURE 72 SUN PHARMACEUTICALS INDUSTRIES LTD. NET SALES 2013-2015 ($ MILLION)
